Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	bioRxiv (Dec 12, 2024)
1. Verfasser:	Lei, Jonathan T
Weitere Verfasser:	Dobrolecki, Lacey E, Huang, Chen, Srinivasan, Ramakrishnan R, Vasaikar, Suhas V, Lewis, Alaina N, Sallas, Christina, Zhao, Na, Cao, Jin, Landua, John D, Chang In Moon, Liao, Yuxing, Hilsenbeck, Susan G, Osborne, C Kent, Rimawi, Mothaffar F, Ellis, Matthew J, Petrosyan, Varduhi, Wen, Bo, Li, Kai, Saltzman, Alexander B, Jain, Antrix, Malovannaya, Anna, Wulf, Gerburg M, Marangoni, Elisabetta, Li, Shunqiang, Kraushaar, Daniel C, Wang, Tao, Damodaran, Senthil, Zheng, Xiaofeng, Meric-Bernstam, Funda, Echeverria, Gloria V, Meenakshi Anurag, Chen, Xi, Welm, Bryan E, Welm, Alana L, Zhang, Bing, Lewis, Michael T
Veröffentlicht:	Cold Spring Harbor Laboratory Press
Schlagworte:	AstraZeneca AbbVie Inc Pfizer Inc Envigo Seattle Genetics Inc Antagonism Models Experimental research Cancer therapies Cytokeratin Biotechnology Oncology Disease management Breast cancer Transcriptomics Proteomics Royalties Histone deacetylase Stockholders Biomarkers Research funding Licenses Carboplatin Chemotherapy Patients Chemoresistance Fees & charges Xenografts
Online-Zugang:	Citation/Abstract Full Text - PDF Full text outside of ProQuest
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!

Schreiben Sie den ersten Kommentar!